Characteristics Frequency %
Primary tumour site
Mouth 14 25.5
Oropharynx 17 30.9
Larynx 16 29.1
Hypopharynx 2 3.6
Salivary glands 5 9.1
Unknown 1 1.8
Tumour size (TNMa)
T1 8 14.5
T2 10 18.2
T3 10 18.2
T4 17 30.9
T4a 5 9.1
Not informed 5 9.1
Lymph node involvement (TNMa)
N0 25 45.5
N1 14 25.5
N2a 10 18.2
N2b 2 3.6
N3 3 5.5
Not informed 1 1.8
Clinical stage
I 3 5.5
II 8 14.5
III 17 30.9
IV 20 36.4
IVa 7 12.7
Histopathological diagnosis
Squamous cell carcinoma 47 85.5
Others 8 14.5
Oncological treatment
Radiotherapy 5 9.1
Radiotherapy and surgery 18 32.7
Radiotherapy and chemotherapy 18 32.7
Radiotherapy, surgery, and chemotherapy 14 25.5
Post-treatment period (months)
8 - 18 16 29.1
19 - 36 19 34.5
37 - 54 11 20
55 - 72 9 16.4
Dose (Gy)
≥ 22 < 50.5 4 7.3
≥ 50.5 < 64 20 36.4
≥ 64 ≤ 70.2 31 56.4

aTNM, as proposed by the International Union against Cancer (UICC). Source: https://www.uicc.org/resources/tnm
T4a = Tumours in advanced stages invading adjacent anatomical structures, depending on the tumour origin.
N2a = Single regional lymph node involved, ipsilateral to the tumour.
N2b = Multiple regional lymph nodes involved, ipsilateral to the tumour.
IVa = T4a, N0 or N1, M0 or, T1 to T4a, N2, M0.